



Integrating Umbilical Cord Blood Lipid Profile with Liver and Renal Function Tests: Implications for Fetal Development and Health

Jayanti Rawat (Dept. of Medical Biochemistry), Research Scholar, SunRise University, Alwar (Rajasthan)
Dr. Sandeep kr. Sharma, Assistant Professor (Dept. of Medical Biochemistry), SunRise University, Alwar (Rajasthan)

Abstract

The umbilical cord blood serves as a crucial source of information about the prenatal environment and fetal health. In recent years, there has been growing interest in exploring the relationship between umbilical cord blood lipid profiles and liver and renal function tests in newborns, aiming to understand their implications for fetal development and subsequent health outcomes. This paper reviews existing literature on this topic, highlighting the potential significance of integrating lipid profile data with liver and renal function tests in assessing fetal well-being. We discuss the physiological basis of lipid metabolism during fetal development, the influence of maternal factors on cord blood lipid composition, and the associations between altered lipid profiles and adverse fetal outcomes. Furthermore, we explore the interplay between lipid metabolism and liver and renal function in the context of fetal health, emphasizing the importance of a holistic approach to prenatal screening and monitoring. Finally, we propose avenues for future research to enhance our understanding of these complex interactions and their clinical implications for maternal and neonatal healthcare.

Keywords: Umbilical cord blood, Lipid profile, Liver function tests, Renal function tests, Fetal development, maternal factors, Prenatal screening, Neonatal healthcare

1. Introduction

The Intrauterine environment plays a critical role in shaping fetal development and long-term health outcomes. Among the various biomarkers available for assessing fetal well-being, umbilical cord blood offers valuable insights into the prenatal environment and the physiological status of the fetus at the time of birth. In recent years, researchers have begun to explore the relationship between umbilical cord blood lipid profiles and markers of liver and renal function, recognizing the potential implications for fetal health and development.

The most frequent components of a serum lipid profile are triglycerides (TG), total cholesterol (TC) and its subtypes, low-density lipoproteins cholesterol (LDL-C), and high-density lipoproteins cholesterol (HDL-C). (High-density lipoprotein-C) as discussed by Neal and John in 2016. In wealthy nations, researchers have extensively investigated the distribution of serum levels of various lipid fractions and set normative values for adults and children. However, in underdeveloped countries, this kind of research is lacking, particularly for newborn newborns. Numerous international research on children and adolescents have confirmed the impact of age, environment, and genetics on their physiology by demonstrating large variability in serum lipids. It is well-established that there is a correlation between genetics and environmental factors that increases the likelihood of coronary vascular disease (CVD) and high blood TC levels in families (El-Hazmi MA, Warsy, 2001; Akuyam et al., 2007). While there is a lot of variation in the reference ranges for cord blood lipids between full-term newborns in developing countries and the established international standard, the ranges for pre-term infants are consistently higher than those for full-term infants (Aletayeb et al., 2013; Mago et al., 2013).

While levels of total cholesterol (TC) in cord blood are lower in preterm children, those born at full term approach one-third of adult values, with LDL-C accounting for 50-60% and HDL-C for 40-50%. Higher serum lipids in preterm newborns may be attributable, in part, to insufficient enzymatic activity (lipoprotein lipase, hepatic lipase, and lecithin cholesterol acyl-transferase) in near-term neonates as compared to their term counterparts (Kazemi SA, Sadeghzadeh, 2014). There seems to be an inverse relationship between the decrease in plasma cholesterol that happens at term and the rise in LDL-C absorption by the foetal adrenal gland



for steroid hormone production. The adrenals' inefficiency in HDL-C metabolism may explain why there is a decline in HDL-C levels by term, when these enzymes are more mature and active (Spear et al, 1991). An higher risk of developing CVD later in life has been associated with elevated lipoprotein concentrations in preterm neonates, suggesting that the pathophysiology of atherosclerosis begins early in life (Kelishadi and Poursafa, 2014). According to Millán et al. (2014), one index that can be derived from blood lipid parameter ratios is the atherogenic index of plasma (AIP), which is the logarithm of the ratio TG/HDL-C. This index was found to be a good predictor of atherosclerosis risk in cord blood and sera of participants from birth onto childhood, adolescence, and adulthood.

The average plasma TC level is 68 mg/dl (1.80 mmol/L) at birth, but it quickly doubles by the time the neonatal period is over. At the onset of puberty, TC levels continue to climb steadily until they reach 160 mg/dl (4.14 mmol/L), after which they briefly decline (in men because of a decrease in HDL and in females because of a decrease in LDL). According to Yildiz et al. (2009), there is a correlation between lower levels of cord blood lipids in full-term newborns and the risk of late onset neonatal sepsis. This is thought to be due to defective TG-mediated neutralisation of lipopolysaccharides. Therefore, it is important to evaluate cord blood and neonatal lipids for prognosis. Despite the abundance of research on cord blood lipid reference ranges in both industrialised and developing nations, the limited number of studies that have measured these parameters in Nigeria (all from the south) is concerning (Ayoola et al, 2012).

Testing the Liver Function of the Umbilical Cord

In order to improve clinical outcomes, biochemical indicators are essential for precise diagnosis, risk assessment, and treatment selection. There has been tremendous development in the study and use of biomarkers throughout the years. The National Institute of Health (NIH) defined a biomarker in 2001 as a characteristic that may be consistently tested and analysed to indicate normal biology, pathologic processes, or pharmacologic reactions to a therapeutic intervention. According to Ramachandran (2006). Standard renal function tests include creatinine, urea, uric acid, and electrolytes; however, several studies have confirmed and strengthened the usefulness of indicators such cystatin C and -Trace Protein. Babies' biological systems need bilirubin, which is more than simply an annoying chemical with bad consequences; it's an essential antioxidant. Conversely, the central nervous system might be negatively impacted by high bilirubin levels throughout development. Without conjugation, unconjugated bilirubin poses a threat to numerous cellular types, intracellular organelles, and physiological activities. At least in the initial phases of damage, bilirubin-induced cell death may rely on apoptosis. However, neuronal cell loss, severe reactive astrocytosis, and necrosis are hallmarks of later neuropathologic changes in kernicterus. Referenced in the 2011 study by Barikbin et al.

There is a high risk of neonatal death, long-term neurodevelopmental effects such cerebral palsy, sensorineural hearing loss, and intellectual disabilities, and jaundice can progress to acute bilirubin encephalopathy (ABE) in certain infants. Thus, a follow-up consultation should be scheduled for newborns who are discharged within 48 hours to check for any serious jaundice or other complications, according to the American Academy of Paediatrics (AAP). In order to prevent severe hyperbilirubinemia and its harmful consequences, doctors need accurate markers to predict which new borns will have high levels of the blood bilirubin (Mwaniki et al., 2012; Khairy et al., 2019; Olusanya et al., 2015). Serum albumin levels may be a predictor of hyperbilirubinemia because bilirubin is transported in the plasma as a dianion bound tightly but reversibly to albumin. The unbound or loosely bound portion of bilirubin, also called free bilirubin, can more easily leave the intravascular space and cross the intact blood-brain barrier (Memon et al, 2016).

One valuable additional metric in the treatment of neonatal hyperbilirubinemia is the bilirubin albumin ratio, which is a surrogate for free bilirubin. It gives the doctor a good idea of how much bilirubin is bound to albumin until they can measure the amount of free bilirubin or



albumin binding reserve in a clinical setting (Khairy et al., 2019). The most notable change that occurs immediately after birth is the rapid transition from a low-oxygen environment (the foetus) to a high-oxygen one (the infant). During this atmospheric shift, the content of oxygen more than doubles. This sets off a chain reaction of red blood cell destruction and heme metabolism, despite the fact that antioxidant levels are low after birth. Hydrogen peroxide levels rise in tandem with oxygen levels during the foetal-to-extra-fetal environment shift. Chou et al. (2014) found that hydrogen peroxide can cause bilirubin production by damaging the membranes of red blood cells. In the first twenty-four hours after birth, a baby's blood glucose level drops to 60–70% of the mother's level. The minimum value is recorded at the third hour of life. Blood glucose levels temporarily rise over the following 24 hours. This happens as a result of using up extra nutrients after eating, inducing gluconeogenesis, and glycogenolysis of liver reserves. Consequently, glucose levels increase and typically stabilise between 65 and 70 mg/dL after the initial 3 to 4 hours (Wilker, 2012). Prior to reaching stability, extremely low levels may be experienced at around 3–4 days of age. Consequently, it is common for neonates to experience temporary low blood glucose levels in the hours following delivery. This is because their glucose source changes from a constant transplacental supply from the mother's blood to an intermittent supply that they obtain through nursing. Neurologic problems include cerebral palsy, occipital lobe epilepsy, visual difficulties, cognitive impairment, and permanent brain damage can result from severe or recurring hypoglycemia. References: (Boluyt et al., 2006; Duvanel et al., 1999). There is a correlation between glycuria and symptoms of hyperglycemia, osmotic diuresis, intra-ventricular haemorrhage, neuromuscular complications, and cognitive impairment in those who survive. Consequently, screening for metabolic abnormalities including hypoglycemia and hyperglycemia is essential for all neonates at risk. Appropriate food regimens and prompt intervention after metabolic disturbance diagnosis can lessen their occurrence and severity (Charles and Eugina, 2005; Burns et al, 2008). "Hypoprosis" occurs when blood glucose levels drop below 45 mg/dL (Cornblath and Schwartz, 1999). According to Pati et al. (2001), hyperglycemia is defined as blood glucose levels more than 125 mg/dL. The typical range for cord blood sugar levels is 45–96 mg/dL, with an average of 73 mg/dL. Babies typically have blood glucose levels ranging from 40 to 97 mg/dL between the first and twelfth hours of life (Acharya and Wayne, 1965). There is a lack of study on cord blood glucose measurements and the risk of irreversible hypoglycemic impairment in newborns below a certain threshold. A potential solution to the problem of newborn morbidity could be to use cord blood glucose levels as a screening tool for hypoglycemia or hyperglycemia, if a correlation between the two can be found. Therefore, neonatal hypoglycemia can be predicted early when cord blood sugar levels are low in newborns. Preventing and treating newborn hypoglycemia and associated complications is possible with routine cord blood glucose estimation, which can detect infants at risk of imminent hypoglycemia. Glucometer Random Blood Sugar (GRBS) assessments of cord blood can also help prevent early treatments like venous blood collection and heel pricking in neonates. Almost every cell in your body has alkaline phosphatase. This includes your red blood cells, liver, bile ducts, and bones. Many different substances can have their phosphates removed by this hydrolase enzyme. Depending on where it originates in the body, it manifests in many ways. It has a crucial role in skeletal development and liver metabolism. Because of its widespread distribution in these regions, its bloodstream content is used as a biomarker to help detect hepatitis and osteomalacia (Lubin and Shearer, 2007). Abnormal blood alkaline phosphatase levels could indicate issues with the gall bladder, bones, or liver. Kidney tumours, infections, and malnutrition are all associated with elevated blood alkaline phosphatase levels (Rennie et al., 2009).

Evaluation of Renal Function in Umbilical Cord Blood

Level of Creatinine : Evaluation of renal function in umbilical cord blood often includes the measurement of creatinine levels. Creatinine is a waste product generated from the breakdown



of creatine, a molecule found in muscles. It is primarily excreted by the kidneys, making it a valuable marker for assessing renal function, particularly glomerular filtration rate (GFR), which is a measure of the kidneys' ability to filter waste products from the blood. Creatinine levels in umbilical cord blood reflect the newborn's renal function at birth. The concentration of creatinine in the blood is influenced by factors such as renal blood flow, glomerular filtration rate, tubular secretion, and maternal creatinine levels. GFR represents the rate at which the kidneys filter blood per unit of time. Creatinine is freely filtered by the glomeruli and is not reabsorbed by the renal tubules to a significant extent. Therefore, serum creatinine levels are inversely related to GFR: as GFR decreases, serum creatinine levels increase. Abnormal creatinine levels in umbilical cord blood may indicate impaired renal function in the newborn, which could be due to congenital anomalies, renal hypoperfusion, or other renal disorders. Early detection of renal dysfunction allows for prompt intervention and management to prevent complications and optimize renal outcomes. Creatinine levels in umbilical cord blood also provide indirect information about maternal renal function during pregnancy. Maternal creatinine crosses the placenta, and fetal kidneys excrete it along with their own creatinine. Discrepancies between maternal and fetal creatinine levels may indicate maternal renal insufficiency or conditions affecting placental function. Studies have shown that abnormal creatinine levels in umbilical cord blood are associated with adverse neonatal outcomes, including respiratory distress syndrome, perinatal asphyxia, and neonatal mortality. Monitoring creatinine levels in cord blood may help predict neonatal outcomes and guide appropriate interventions. Creatinine levels in umbilical cord blood can also provide insights into the newborn's renal adaptation to extrauterine life. Physiological changes occur in the neonatal kidneys after birth as they assume the responsibility for maintaining fluid and electrolyte balance and excreting waste products. Monitoring creatinine levels over time allows healthcare providers to assess renal adaptation and function postnatally. Creatinine levels in umbilical cord blood can provide insights into the maturity of the fetal kidneys. Lower creatinine levels may indicate immaturity of renal function, while higher levels may suggest more developed kidneys. This information can be valuable for assessing the readiness of the newborn's kidneys to function independently after birth. Studies have found correlations between creatinine levels in umbilical cord blood, birth weight, and gestational age. Lower creatinine levels have been observed in preterm infants and those with low birth weight, reflecting immaturity of renal function and potential renal compromise associated with prematurity. Abnormal creatinine levels in umbilical cord blood may serve as an early diagnostic marker for renal disorders, such as renal dysplasia, obstructive uropathy, or congenital anomalies of the kidney and urinary tract (CAKUT). Elevated creatinine levels may indicate impaired renal function, prompting further evaluation and diagnostic tests. Creatinine levels in umbilical cord blood have been associated with neonatal morbidity and mortality. Higher creatinine levels at birth have been linked to increased risks of adverse outcomes such as neonatal intensive care unit (NICU) admission, respiratory distress syndrome, and mortality, highlighting the prognostic value of creatinine in predicting neonatal health outcomes. Maternal factors, such as maternal age, maternal health conditions (e.g., hypertension, diabetes), and maternal medications, can influence creatinine levels in umbilical cord blood. Understanding the impact of maternal factors on neonatal creatinine levels is essential for interpreting results accurately and assessing the newborn's renal function in context. Creatinine levels in umbilical cord blood can provide baseline data for long-term follow-up of renal function in neonates. Serial monitoring of creatinine levels during infancy and childhood allows for the assessment of renal growth and function over time and the early detection of renal abnormalities or progressive renal disease. In high-risk neonates, such as those born prematurely, with intrauterine growth restriction (IUGR), or with perinatal complications, monitoring creatinine levels in umbilical cord blood can help identify renal dysfunction early and guide appropriate interventions to prevent or mitigate renal-related morbidity and mortality. Creatinine levels in umbilical cord blood are



the subject of ongoing research to better understand their role in assessing renal function and predicting neonatal outcomes. Advances in technology and analytical methods may further enhance the utility of creatinine as a biomarker for renal health in neonates and contribute to the development of novel diagnostic and therapeutic strategies. The rate at which the body creates creatinine, a byproduct of creatine phosphate breakdown in muscle, is relatively constant and is proportional to the mass of the muscle. An established measure for evaluating renal function is creatinine. Females typically have a creatinine clearance rate of 100–130 ml/min, while males typically have a range of 110–150 ml/min (Yuegang et al, 2008). In order to determine the glomerular filtration rate, the National Kidney Disease Education Programme suggests using the serum creatinine concentration. One way to monitor the progression of renal disease is via the creatinine clearance test. Renal failure is commonly considered when serum creatinine levels above the upper limit of the "normal" period. Chronic renal failure and uremia cause a gradual decrease in creatinine excretion by the glomeruli and tubules. Muscle mass is just one of several factors that affect creatinine levels; other factors include activity, diet, health, muscle function, and muscle composition (Miller et al., 2005; Edmund and David, 2006). Some patients with renal failure may have an elevated tubular creatinine secretion, which could lead to an inaccurate negative result. Patients with hyperthyroidism, anaemia, paralysis caused by muscular dystrophy, or leukaemia will have increased readings. Shock, polycystic kidney disease, glomerulonephritis, acute tubular necrosis, dehydration, and congestive heart failure are all linked to decreased levels (Branten et al, 2005). Creatinine is the gold standard for measuring renal function in both adults and children.

Urea : Urea is filtered by the glomeruli in the kidneys and then reabsorbed and partially excreted in the urine. Therefore, the level of urea in the blood reflects the balance between its production and renal clearance. Elevated urea levels may indicate impaired renal clearance, suggesting reduced glomerular filtration rate (GFR) or tubular dysfunction. Similar to creatinine, urea levels in umbilical cord blood can provide insights into GFR, which is a measure of the kidneys' ability to filter waste products from the blood. Decreased GFR leads to reduced urea clearance and consequently elevated urea levels in the blood. Urea levels in umbilical cord blood also reflect the neonate's renal adaptation to extrauterine life. During the transition from intrauterine to extrauterine environment, the newborn's kidneys undergo significant changes to regulate fluid and electrolyte balance and excrete waste products efficiently. Monitoring urea levels helps assess the adequacy of renal adaptation and function in the neonatal period. Abnormal urea levels in umbilical cord blood may indicate alterations in renal perfusion or function. Reduced renal blood flow or renal hypoperfusion can lead to decreased urea excretion and elevated urea levels in the blood. This could be due to conditions such as hypovolemia, hypotension, or renal artery stenosis. Elevated urea levels in umbilical cord blood may serve as an early marker for renal disorders or kidney injury in newborns. Conditions such as renal dysplasia, urinary tract obstruction, or congenital anomalies affecting renal function may result in impaired urea clearance and increased urea levels in the blood. Studies have shown associations between abnormal urea levels in umbilical cord blood and adverse neonatal outcomes, including neonatal morbidity and mortality. Elevated urea levels at birth may predict an increased risk of neonatal complications, such as respiratory distress syndrome, sepsis, or renal failure. Maternal factors, such as maternal renal function, maternal health conditions (e.g., hypertension, diabetes), and maternal medications, can influence urea levels in umbilical cord blood. Understanding the impact of maternal factors on neonatal urea levels is essential for accurate interpretation and assessment of renal function in newborns. Urea levels in umbilical cord blood can also reflect the neonate's fluid status at birth. Elevated urea levels may suggest dehydration or inadequate fluid intake during labor and delivery, leading to increased urea concentration in the blood. Conversely, low urea levels may indicate overhydration or excessive fluid administration. Urea is freely filtered by the placenta, and both maternal and fetal kidneys contribute to urea clearance. Monitoring urea levels in umbilical



cord blood provides insights into maternal-fetal renal function and the exchange of urea across the placenta. Discrepancies between maternal and fetal urea levels may indicate alterations in maternal renal function or placental function. Maternal nutrition can influence urea levels in umbilical cord blood, as urea is a byproduct of protein metabolism. Maternal malnutrition or protein deficiency may result in lower urea levels in cord blood, reflecting reduced protein intake and metabolism during pregnancy. Urea levels in umbilical cord blood can be influenced by factors related to labor and delivery, such as the duration of labor, mode of delivery (vaginal vs. cesarean section), and intrapartum events. Prolonged labor or fetal distress during delivery may lead to changes in renal perfusion and metabolism, affecting urea levels in cord blood. Urea levels in umbilical cord blood may serve as a predictor of neonatal renal function and the risk of renal-related complications in the immediate postnatal period. High urea levels at birth may indicate potential challenges in renal adaptation and function, requiring close monitoring and early intervention. Urea is excreted into the amniotic fluid by the fetus and can be reabsorbed by the fetus or swallowed, contributing to the regulation of amniotic fluid volume. Monitoring urea levels in umbilical cord blood may provide insights into amniotic fluid dynamics and fetal renal function during gestation.

Medications administered to the mother during labor or interventions such as epidural anesthesia or oxytocin augmentation may impact fetal renal function and urea levels in umbilical cord blood. Understanding the effects of these medications and interventions on neonatal renal function aids in interpreting urea levels and assessing renal health. Urea is involved in the urinary concentration process, where it contributes to the formation of the renal medullary osmotic gradient. Monitoring urea levels in umbilical cord blood provides insights into the fetal renal concentrating ability and the development of nephron function, which is crucial for maintaining fluid and electrolyte balance postnatally. Urea levels in umbilical cord blood may vary based on factors such as birth order and the presence of multiple gestations. Firstborn infants or those from multiple pregnancies may have higher urea levels due to differences in placental perfusion, uteroplacental circulation, or fetal renal development. Urea levels in umbilical cord blood are particularly relevant in preterm infants, as renal immaturity and functional impairment are common in this population. Monitoring urea levels in cord blood helps assess renal function in preterm neonates and identify those at risk of renal-related complications, such as electrolyte imbalances or acute kidney injury. Elevated urea levels in umbilical cord blood have been associated with an increased risk of neonatal jaundice. Urea competes with bilirubin for binding sites on albumin, potentially displacing bilirubin and increasing its circulation in the bloodstream, leading to hyperbilirubinemia and jaundice in newborns. Urea levels in umbilical cord blood may be affected by fetal growth restriction (FGR) or intrauterine growth restriction (IUGR). Reduced urea levels in cord blood have been observed in fetuses with FGR, reflecting decreased renal perfusion and metabolic alterations associated with intrauterine growth restriction. Abnormal urea levels in umbilical cord blood have been correlated with neonatal hypotension, a common complication in the early postnatal period. Elevated urea levels may indicate renal hypoperfusion or compromised renal function, contributing to the development of hypotension in neonates. Studies have investigated the association between urea levels in umbilical cord blood and long-term renal outcomes in children and adults. Abnormal urea levels at birth may predict an increased risk of chronic kidney disease, hypertension, or renal dysfunction later in life, highlighting the importance of early identification and intervention in optimizing long-term renal health.

Beta-2-microglobulin : The molecular weight of the small protein beta-2-microglobulin (B2M) is 11.8 kDa. On the surface membrane of almost every nucleated cell, you can find it as the beta chain of the major histocompatibility complex (MHC). Serum and synovial fluid are the most prevalent sources, but it is present in many other body fluids and is eliminated during membrane turnover. The glomerular wall is permeable to unbound B2M because to its high sieving coefficient. Similar to other proteins with a low molecular weight, it undergoes



reabsorption and catabolism in the proximal tubules. According to Karlsson et al. (1980) and Berggård and Bearn (1968), tubular dysfunction is indicated by elevated B2M levels in the urine. Virus infections, inflammation, and many types of cancer are associated with elevated serum B2M concentrations, which are produced from the MHC. The ratio of cystatin C to B2M in blood samples taken at the same time has been suggested as a diagnostic criterion for lymphoproliferative disease after transplantation. Glucocorticoids decrease B2M concentrations in a way that is dose-dependent. These non-renal variables reduce B2M usefulness as a GFR marker value. (References: Cooper et al., 1984; Fahey et al., 1990). Beta-2-microglobulin is primarily reabsorbed by the renal tubules, and its levels in the blood are influenced by tubular reabsorption and catabolism. Elevated levels of beta-2-microglobulin in umbilical cord blood may indicate impaired tubular function, such as proximal tubular dysfunction, tubulointerstitial nephropathy, or renal tubular acidosis. Although beta-2-microglobulin is primarily a marker of tubular function, its levels in umbilical cord blood can also reflect changes in glomerular filtration rate (GFR). Alterations in GFR can affect the delivery of beta-2-microglobulin to the renal tubules, influencing its levels in the blood. Abnormal levels of beta-2-microglobulin in umbilical cord blood may serve as a diagnostic marker for renal tubular disorders or tubulointerstitial nephropathies in newborns. Conditions such as Fanconi syndrome, renal tubular acidosis, or acute tubular necrosis may lead to increased beta-2-microglobulin levels due to impaired tubular reabsorption or increased tubular turnover. Monitoring beta-2-microglobulin levels in umbilical cord blood may help predict the risk of neonatal renal dysfunction or renal-related complications in the immediate postnatal period. Elevated beta-2-microglobulin levels at birth may indicate potential challenges in renal tubular function and adaptation, requiring close monitoring and intervention.

Beta-2-microglobulin is freely filtered by the glomeruli and crosses the placenta, contributing to its presence in umbilical cord blood. Monitoring beta-2-microglobulin levels allows for the assessment of maternal-fetal renal exchange and potential alterations in fetal renal function during gestation. Elevated levels of beta-2-microglobulin in umbilical cord blood have been associated with neonatal infections, particularly those affecting the urinary tract or causing systemic inflammation. Inflammatory processes and immune responses associated with infections may lead to increased renal tubular turnover and release of beta-2-microglobulin into the bloodstream. Studies have investigated the association between beta-2-microglobulin levels in umbilical cord blood and long-term renal outcomes in children and adults. Abnormal beta-2-microglobulin levels at birth may predict an increased risk of chronic kidney disease, proteinuria, or renal dysfunction later in life, highlighting the importance of early identification and intervention in optimizing long-term renal health. B2M levels in umbilical cord blood can serve as a marker for assessing potential drug toxicity or exposure during pregnancy. Certain medications or toxins may affect renal tubular function and lead to alterations in B2M levels in cord blood. Monitoring B2M levels can help identify neonates at risk of drug-induced renal injury and guide appropriate management. Maternal health conditions, such as diabetes, hypertension, or autoimmune diseases, can influence B2M levels in umbilical cord blood. These conditions may affect maternal renal function and placental transfer of B2M to the fetus, leading to changes in neonatal B2M levels. Understanding the impact of maternal health conditions on neonatal B2M levels aids in interpreting results accurately. B2M levels in umbilical cord blood provide insights into fetal renal development and function during gestation. Monitoring changes in B2M levels throughout pregnancy may help assess the progression of renal maturation and the development of renal tubular integrity in the fetus. Birth trauma or perinatal stressors, such as asphyxia or meconium aspiration, can impact neonatal renal function and tubular integrity, affecting B2M levels in umbilical cord blood. Elevated B2M levels may indicate renal tubular injury or stress response secondary to perinatal events, prompting further evaluation and management. Maternal substance use, including tobacco, alcohol, or illicit drugs, may influence B2M levels in umbilical cord blood. Exposure



to substances that affect renal function or tubular integrity can lead to alterations in neonatal B2M levels, reflecting potential fetal renal compromise or injury. Intrauterine growth restriction (IUGR) may impact fetal renal development and function, leading to changes in B2M levels in umbilical cord blood. Reduced renal perfusion or altered tubular function associated with IUGR may result in abnormal B2M levels, indicating potential renal dysfunction or adaptive changes in the foetus. Elevated B2M levels in umbilical cord blood have been observed in neonates with respiratory distress syndrome (RDS). The pathophysiology of RDS involves pulmonary immaturity and surfactant deficiency, which can lead to hypoxic-ischemic injury and renal tubular dysfunction, reflected by increased B2M levels. Assessing B2M levels in conjunction with other renal biomarkers, such as creatinine or urea, enhances the comprehensive evaluation of neonatal renal function. Combining multiple biomarkers allows for a more nuanced assessment of renal health and facilitates early detection of renal dysfunction or injury in newborns. Elevated B2M levels in umbilical cord blood have been associated with neonatal sepsis, particularly in cases of systemic bacterial or viral infections. Inflammatory responses associated with sepsis can lead to renal tubular injury or dysfunction, resulting in increased B2M levels. Monitoring B2M levels aids in the early detection and management of sepsis-related renal complications in newborns. B2M levels in umbilical cord blood may provide insights into renal perfusion during labor and delivery. Changes in fetal renal perfusion or renal blood flow dynamics can impact B2M clearance and levels in cord blood, reflecting alterations in renal hemodynamics or placental function during the perinatal period. In pregnancies involving maternal renal transplant recipients, monitoring B2M levels in umbilical cord blood helps assess fetal renal function and the impact of maternal renal status on the fetus. Elevated B2M levels may indicate potential renal compromise in the fetus due to maternal factors or immunosuppressive therapy. Assessing B2M levels in umbilical cord blood and other fluid compartments, such as amniotic fluid or neonatal urine, allows for comprehensive evaluation of renal function and dynamics. Correlating B2M levels across different fluid compartments provides insights into renal physiology, tubular integrity, and the exchange of solutes between fetal and maternal compartments. In cases of neonatal renal transplantation, monitoring B2M levels in umbilical cord blood may aid in assessing pre-transplant renal function and predicting post-transplant outcomes. Normal B2M levels in cord blood suggest adequate renal function and may be indicative of favorable outcomes following transplantation.

2. Physiological Basis of Lipid Metabolism in Fetal Development

Lipids serve as a vital energy source for the developing fetus. Fatty acids derived from maternal circulation or synthesized de novo in the fetal liver are oxidized to generate adenosine triphosphate (ATP), providing energy for cellular processes, tissue growth, and organ development. Lipids are integral components of cell membranes, contributing to membrane fluidity, stability, and function. Phospholipids, cholesterol, and glycolipids are essential for the formation of lipid bilayers, which constitute the structural framework of cell membranes in developing tissues and organs. Lipids, primarily triglycerides, serve as energy storage molecules in the form of lipid droplets within adipose tissue and other fetal tissues. Triglycerides stored in adipocytes can be mobilized and hydrolyzed into fatty acids to meet the energy demands of the fetus during periods of fasting or increased metabolic activity. Lipids serve as precursors for the synthesis of various signaling molecules, including prostaglandins, eicosanoids, and steroid hormones, which play critical roles in regulating cellular processes, immune responses, and developmental pathways during fetal growth and differentiation. Lipids are transported across the placenta from the maternal to the fetal circulation via specialized transport mechanisms, including lipoproteins such as chylomicrons, very-low-density lipoproteins (VLDL), and high-density lipoproteins (HDL). These lipoproteins facilitate the transport of cholesterol, triglycerides, phospholipids, and fat-soluble vitamins across the placental barrier to meet the fetal requirements for growth and development. The fetal liver



plays a central role in lipid metabolism, including lipid synthesis, storage, and metabolism. Hepatocytes synthesize fatty acids, cholesterol, and phospholipids de novo or from precursors obtained from the maternal circulation. Additionally, the fetal liver regulates the synthesis and secretion of lipoproteins, such as VLDL, which transport lipids to peripheral tissues for energy production or storage. The placenta acts as a crucial interface for lipid transport and metabolism between the maternal and fetal circulations. Placental trophoblasts express various transporters and receptors involved in the uptake, metabolism, and transfer of lipids, ensuring adequate lipid supply to the developing fetus while maintaining maternal lipid homeostasis. Dysregulation of placental lipid metabolism can impact fetal growth and development and contribute to adverse pregnancy outcomes. Lipid metabolism in the fetus is tightly regulated by hormonal, nutritional, and environmental factors. Hormones such as insulin, glucagon, leptin, and cortisol play key roles in modulating lipid synthesis, storage, and utilization in fetal tissues. Nutritional factors, including maternal diet and nutrient availability, influence fetal lipid metabolism and composition, with maternal malnutrition or excessive caloric intake leading to alterations in fetal lipid profiles and metabolic programming. Lipids play a crucial role in neurological development during fetal gestation. Lipids, particularly omega-3 and omega-6 fatty acids, are essential for the formation of neuronal membranes and the myelin sheath, which insulates nerve fibers and facilitates rapid nerve conduction. Adequate lipid supply during fetal development is vital for optimal brain growth, neurogenesis, and cognitive function later in life. Fetal lipid metabolism exhibits remarkable adaptability to maternal nutrient availability. In response to maternal nutritional status, fetal lipid metabolism undergoes adjustments to optimize nutrient uptake, storage, and utilization. During periods of maternal undernutrition, fetal lipid metabolism may prioritize energy conservation and storage, leading to alterations in lipid partitioning and adipose tissue development to ensure adequate nutrient availability for fetal growth. The placenta synthesizes and transports lipids to meet the metabolic demands of the developing fetus. Placental trophoblasts utilize maternal-derived fatty acids and cholesterol to synthesize lipids, including triglycerides and phospholipids, which are then packaged into lipoproteins for transport across the placental barrier. Placental lipid transport mechanisms ensure the efficient delivery of lipids to fetal tissues while maintaining maternal-fetal lipid homeostasis. Fetal lipid metabolism is subject to epigenetic regulation, which can influence gene expression patterns and metabolic programming. Epigenetic modifications, such as DNA methylation and histone acetylation, regulate the expression of genes involved in lipid metabolism pathways, shaping fetal lipid profiles and metabolic phenotypes. Alterations in epigenetic regulation of lipid metabolism may contribute to the developmental origins of metabolic diseases in adulthood. Maternal obesity and diabetes mellitus can have profound effects on fetal lipid metabolism. Maternal obesity is associated with increased levels of circulating fatty acids and pro-inflammatory cytokines, which can cross the placenta and affect fetal lipid uptake and metabolism. Maternal diabetes alters fetal insulin signaling and lipid partitioning, leading to alterations in lipid metabolism and storage in fetal tissues, predisposing offspring to metabolic disorders and obesity. In addition to the liver, other fetal organs, such as the adipose tissue, heart, and skeletal muscle, play roles in lipid transport and metabolism. Adipose tissue serves as a major site for lipid storage and mobilization, providing a reservoir of energy for fetal growth and development. The fetal heart utilizes fatty acids as a primary energy source for cardiac metabolism, while skeletal muscle contributes to lipid oxidation and glucose uptake. Maternal hormones, including estrogen, progesterone, and placental hormones such as human chorionic gonadotropin (hCG), play regulatory roles in fetal lipid metabolism. These hormones influence lipid synthesis, transport, and utilization in fetal tissues, coordinating metabolic adaptations to support fetal growth and development. Dysregulation of maternal hormone levels during pregnancy can disrupt fetal lipid metabolism and contribute to developmental abnormalities.



3. Maternal Factors Influencing Cord Blood Lipid Composition

Maternal factors play a crucial role in influencing the composition of lipids in umbilical cord blood, reflecting the intrauterine environment experienced by the fetus. Here are several maternal factors that can influence cord blood lipid composition:

Maternal Diet: Maternal dietary intake during pregnancy directly influences the composition of lipids in umbilical cord blood. High intake of saturated fats, trans fats, and cholesterol-rich foods can lead to elevated levels of LDL cholesterol and triglycerides in cord blood, predisposing the fetus to dyslipidemia and metabolic disorders later in life. Conversely, maternal consumption of omega-3 fatty acids, found in fatty fish, flaxseeds, and walnuts, can increase the proportion of beneficial HDL cholesterol in cord blood and promote optimal lipid profiles in newborns.

Maternal Obesity: Maternal obesity is associated with alterations in maternal lipid metabolism, leading to increased levels of circulating triglycerides, LDL cholesterol, and free fatty acids. These maternal lipid abnormalities can cross the placenta and impact the lipid composition of umbilical cord blood, predisposing infants to dyslipidemia and metabolic syndrome in early life. Moreover, maternal obesity is linked to chronic low-grade inflammation and oxidative stress, which can further exacerbate lipid disturbances in the fetus.



Fig. 1: Beyond glucose, there are other maternal variables that affect prenatal development abnormalities that are connected to juvenile obesity and subsequent metabolic disorders. Both early and late in pregnancy, these variables affect fetal growth in separate and combined ways. Future generations' health can be enhanced by concentrating on ways to create a healthier intrauterine environment early in pregnancy in order to restore fetal growth patterns. (NBALD non-alcoholic fatty liver disease, FA fatty acid, AA amino acids, TG triglycerides, GWG gestational weight gain, LPL lipoprotein lipase, and BMI body mass index)

https://www.researchgate.net/figure/Multiple-maternal-factors-beyond-glucose-influence-fetal-growth-alterations-that-are_fig1_325048408

Maternal Gestational Diabetes Mellitus (GDM): Maternal GDM is characterized by insulin resistance and hyperglycemia during pregnancy, leading to alterations in maternal lipid metabolism. Elevated maternal blood glucose levels can stimulate fetal insulin production, promoting lipid synthesis and storage in the fetus. Consequently, infants born to mothers with GDM may exhibit dyslipidemia, characterized by elevated levels of triglycerides, LDL cholesterol, and decreased levels of HDL cholesterol in umbilical cord blood, predisposing them to metabolic complications later in life.

Maternal Smoking: Maternal smoking during pregnancy is associated with adverse effects on fetal lipid metabolism and lipid composition. Exposure to cigarette smoke alters placental lipid transport mechanisms, leading to dysregulation of lipid metabolism in the fetus. Infants born to mothers who smoke during pregnancy may have altered levels of cholesterol, triglycerides, and lipoproteins in umbilical cord blood, increasing their risk of cardiovascular disease and metabolic disorders in adulthood.

Maternal Lipid Profile: Maternal lipid profile, including levels of cholesterol, triglycerides, and



lipoproteins, can directly influence the composition of lipids in umbilical cord blood. Maternal dyslipidemia, characterized by elevated levels of LDL cholesterol and triglycerides or decreased levels of HDL cholesterol, is associated with corresponding alterations in cord blood lipid profiles. Elevated maternal levels of LDL cholesterol and triglycerides are particularly associated with adverse fetal lipid profiles and increased risk of metabolic disorders in offspring.

Maternal Medications and Hormonal Status: Certain medications and hormonal factors can influence maternal lipid metabolism and subsequently affect cord blood lipid composition. For example, hormone replacement therapy, corticosteroids, and certain antiretroviral medications may alter maternal lipid profiles, which can impact fetal lipid metabolism and composition. Additionally, maternal hormonal status during pregnancy, including levels of estrogen, progesterone, and thyroid hormones, can influence lipid metabolism and transport across the placenta, contributing to variations in cord blood lipid composition.

Maternal Physical Activity and Stress: Maternal physical activity levels and stress levels during pregnancy may also influence cord blood lipid composition. Regular physical activity during pregnancy is associated with favorable lipid profiles in both maternal and cord blood, characterized by lower levels of triglycerides and LDL cholesterol and higher levels of HDL cholesterol. Conversely, maternal stress and anxiety may lead to dysregulation of lipid metabolism and alterations in cord blood lipid composition, although further research is needed to elucidate the underlying mechanisms.

4. Associations between Altered Lipid Profiles and Adverse Fetal Outcomes

Altered umbilical cord blood lipid profiles, characterized by abnormal levels of cholesterol, triglycerides, and lipoproteins, have been associated with intrauterine growth restriction (IUGR). Infants with IUGR often exhibit dysregulated lipid metabolism, reflecting impaired placental function and inadequate nutrient supply to the fetus. Altered lipid profiles in cord blood may serve as biomarkers for identifying fetuses at risk of IUGR and associated complications, such as preterm birth and neonatal morbidity. Neonates born small for gestational age (SGA) frequently demonstrate abnormalities in umbilical cord blood lipid composition. Low levels of cholesterol, triglycerides, and lipoproteins in cord blood are common features of SGA infants and may indicate suboptimal fetal growth and development. Altered lipid profiles in SGA neonates are suggestive of impaired nutrient uptake and utilization in utero, potentially contributing to increased susceptibility to metabolic disorders and developmental delays in later life. **Syndrome (RDS):** Altered umbilical cord blood lipid profiles have been implicated in the pathogenesis of neonatal respiratory distress syndrome (RDS), a common respiratory complication in preterm infants. Dysregulated lipid metabolism, characterized by reduced levels of surfactant lipids (e.g., phosphatidylcholine) in cord blood, is associated with impaired lung maturation and surfactant deficiency, predisposing neonates to RDS and respiratory insufficiency at birth. Analysis of cord blood lipid profiles may aid in identifying infants at increased risk of RDS and guiding respiratory support interventions. Abnormal umbilical cord blood lipid profiles have been linked to neonatal hypoglycemia, a common metabolic complication in newborns. Infants with dysregulated lipid metabolism, such as those with low levels of triglycerides and free fatty acids in cord blood, may experience disruptions in glucose homeostasis and energy metabolism, leading to hypoglycemia shortly after birth. Cord blood lipid analysis may help identify neonates at risk of hypoglycemia and inform timely glucose monitoring and management strategies to prevent adverse outcomes. Altered umbilical cord blood lipid profiles have implications for long-term metabolic health and cardiovascular risk in offspring. Infants born with dysregulated lipid metabolism, characterized by elevated levels of LDL cholesterol, triglycerides, and inflammatory markers in cord blood, may be predisposed to metabolic syndrome and cardiovascular diseases in adulthood. Early identification of aberrant lipid profiles in cord blood may facilitate targeted interventions to mitigate the long-term consequences of fetal metabolic programming and



reduce the risk of cardiometabolic disorders later in life. Altered umbilical cord blood lipid profiles have been associated with an increased risk of preterm birth. Dysregulated lipid metabolism, characterized by abnormal levels of cholesterol, triglycerides, and fatty acids in cord blood, may reflect underlying disturbances in fetal maturation and placental function, predisposing infants to premature delivery. Preterm infants with aberrant lipid profiles are at higher risk of respiratory distress syndrome, intraventricular hemorrhage, and other complications associated with prematurity. Abnormal umbilical cord blood lipid profiles have been linked to neonatal jaundice, a common condition characterized by elevated levels of bilirubin in the blood. Dysregulated lipid metabolism, particularly impaired bilirubin conjugation and excretion, may contribute to the development of jaundice in newborns. Infants with altered lipid profiles in cord blood may exhibit decreased bilirubin clearance and increased susceptibility to hyperbilirubinemia, necessitating close monitoring and phototherapy intervention to prevent bilirubin encephalopathy and kernicterus.

Altered umbilical cord blood lipid profiles have been implicated in the pathogenesis of neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Dysregulated lipid metabolism in utero, characterized by abnormal levels of fatty acids, phospholipids, and cholesterol in cord blood, may impact fetal brain development and neuronal function, increasing the risk of neurobehavioral abnormalities and cognitive impairments in offspring. Analysis of cord blood lipid profiles may provide insights into early biomarkers of neurodevelopmental risk and inform targeted interventions to support optimal brain development in at-risk infants. Altered umbilical cord blood lipid profiles are associated with fetal programming of metabolic diseases, such as obesity, type 2 diabetes, and cardiovascular disorders. Dysregulated lipid metabolism during fetal development, characterized by elevated levels of triglycerides, LDL cholesterol, and inflammatory markers in cord blood, may induce metabolic imprinting and alter gene expression patterns in fetal tissues, leading to long-term metabolic dysregulation and increased susceptibility to metabolic diseases later in life. Understanding the impact of fetal lipid profiles on metabolic programming is crucial for identifying early predictors of metabolic disorders and implementing preventive strategies to mitigate their onset and progression. Maternal alcohol consumption during pregnancy can perturb umbilical cord blood lipid profiles and increase the risk of fetal alcohol spectrum disorders (FASD). Alcohol exposure in utero alters lipid metabolism in the fetus, leading to abnormal lipid accumulation, oxidative stress, and inflammation in fetal tissues. Infants with dysregulated lipid profiles in cord blood due to maternal alcohol exposure may exhibit growth retardation, developmental delays, and neurobehavioral impairments characteristic of FASD. Early identification of altered lipid profiles in cord blood may aid in the diagnosis and management of FASD and inform targeted interventions to support affected individuals and their families.

5. Interplay between Lipid Metabolism and Liver and Renal Function

The liver and kidneys are integral organs in the regulation of lipid metabolism, each playing distinct yet interconnected roles in maintaining lipid homeostasis throughout the body. The liver serves as a central hub for lipid metabolism, performing essential functions such as lipid synthesis, storage, and secretion of lipoproteins. Additionally, the liver plays a crucial role in the metabolism of cholesterol, triglycerides, and fatty acids, thereby regulating circulating lipid levels. Liver function is closely intertwined with lipid metabolism, as any impairment in hepatic function can disrupt lipid synthesis and clearance pathways, leading to dyslipidemia. In the context of fetal development, perturbations in liver function can have profound implications for lipid metabolism, potentially altering the composition of umbilical cord blood lipids. Aberrations in cord blood lipid profiles, characterized by elevated levels of cholesterol, triglycerides, or altered lipoprotein distribution, may reflect underlying disturbances in hepatic lipid handling during intrauterine life. Similarly, the kidneys play a critical role in lipid metabolism by facilitating the excretion of lipid-derived metabolites and maintaining



electrolyte balance, which indirectly influences lipid metabolism. Renal dysfunction, whether congenital or acquired, can disrupt lipid clearance mechanisms, leading to alterations in circulating lipid levels. Furthermore, impaired renal function can contribute to systemic inflammation and oxidative stress, exacerbating dyslipidemia and metabolic dysfunction. Conversely, dysregulated lipid metabolism can adversely affect liver and renal function, setting the stage for the development of metabolic and renal disorders later in life. Excessive accumulation of lipids within hepatocytes, known as hepatic steatosis, can impair liver function and predispose individuals to non-alcoholic fatty liver disease (NAFLD) and its associated complications. Moreover, dyslipidemia characterized by elevated levels of LDL cholesterol and triglycerides can promote atherosclerosis and cardiovascular disease, further impacting liver and renal function through hemodynamic changes and inflammatory processes. In summary, the interplay between lipid metabolism and liver and renal function is complex and bidirectional, with each component influencing the other throughout fetal development and beyond. Understanding these interrelationships is crucial for unraveling the mechanisms underlying metabolic and renal disorders and developing targeted interventions aimed at preserving fetal health and mitigating long-term health risks.

Hepatic Lipid Metabolism: The liver is not only involved in synthesizing lipids but also in metabolizing dietary fats and cholesterol. It regulates the production of lipoproteins, including very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL), which are crucial for lipid transport in the bloodstream. Moreover, the liver regulates the conversion of excess carbohydrates into fatty acids and their subsequent storage or utilization for energy production.




Fig.2: Physiological and Pathological Interactions between Liver and Kidney

https://link.springer.com/chapter/10.1007/978-4-431-55790-6_11

Renal Lipid Handling: While the kidneys are not traditionally considered major organs in lipid metabolism, recent research highlights their role in lipid handling. The kidneys participate in the reabsorption and excretion of various lipid-derived molecules, such as free fatty acids, phospholipids, and cholesterol. Dysregulated renal lipid handling can contribute to systemic lipid imbalances, impacting overall metabolic health.

Impact of Liver Dysfunction on Lipid Metabolism: Liver diseases, such as hepatitis, cirrhosis, and liver fibrosis, can profoundly affect lipid metabolism. Hepatic dysfunction disrupts the synthesis and secretion of lipoproteins, leading to alterations in circulating lipid levels. Furthermore, impaired liver function compromises the clearance of triglycerides and cholesterol, contributing to dyslipidemia and increased cardiovascular risk.

Renal Dysfunction and Lipid Homeostasis: Chronic kidney disease (CKD) and other renal disorders can perturb lipid metabolism through various mechanisms. Reduced renal clearance of lipoproteins and lipid-derived waste products can lead to dyslipidemia, characterized by elevated levels of LDL cholesterol and triglycerides. Additionally, CKD-induced inflammation and oxidative stress can exacerbate lipid abnormalities, further compromising metabolic health.

Impact of Dyslipidemia on Liver and Renal Function: Dyslipidemia is a well-established risk factor for both hepatic and renal diseases. Elevated levels of LDL cholesterol and triglycerides promote the development of atherosclerosis, which can lead to ischemic injury



and impaired blood flow to the liver and kidneys. Moreover, dyslipidemia contributes to oxidative stress and inflammation, exacerbating tissue damage and functional impairment in these organs.

Fetal Programming and Long-Term Health: The intrauterine environment plays a critical role in programming fetal metabolism and organ development. Dysregulated lipid metabolism and impaired liver and renal function during gestation can have enduring effects on offspring health, predisposing individuals to metabolic syndrome, NAFLD, CKD, and cardiovascular disease later in life.

Hormonal Regulation: Hormones play a crucial role in coordinating lipid metabolism and liver and renal function. Hormones such as insulin, glucagon, and cortisol regulate lipid synthesis, storage, and utilization in the liver and peripheral tissues. Additionally, hormonal imbalances, such as insulin resistance, commonly observed in metabolic disorders, can disrupt lipid metabolism and contribute to hepatic steatosis and dyslipidemia.

By elucidating the intricate connections between lipid metabolism and liver and renal function, researchers aim to identify novel therapeutic targets for preventing and managing metabolic and renal disorders. Moreover, understanding the impact of prenatal factors on long-term health outcomes underscores the importance of early interventions and preventive strategies aimed at optimizing maternal-fetal health and reducing the burden of chronic diseases in future generations.

6. Implications for Prenatal Screening and Neonatal Healthcare

The interplay between lipid metabolism and liver and renal function during fetal development has significant implications for prenatal screening and neonatal healthcare. Understanding these relationships can inform prenatal screening strategies, improve risk assessment for metabolic and renal disorders, and guide interventions aimed at optimizing neonatal health outcomes. Here are some key implications:

- Early Detection of Metabolic and Renal Disorders
- Risk Stratification for Long-Term Health Outcomes:
- Personalized Care and Intervention
- Improving Maternal Health and Pregnancy Outcomes
- Enhancing Neonatal Healthcare Strategies
- Research and Development of Novel Interventions
- Preventive Healthcare Strategies
- Screening for Inherited Metabolic Disorders
- Management of Gestational Complications




Fig.3: Prenatal Testing

https://en.wikipedia.org/wiki/Prenatal_testing

Integrating umbilical cord blood lipid profiles with liver and renal function tests offers a valuable tool for early diagnosis of neonatal metabolic and renal issues. Aberrations in these profiles may indicate underlying problems, such as metabolic syndrome, NAFLD, CKD, and cardiovascular disease later in life, prompting tailored monitoring and interventions. Prenatal screening aids in identifying at-risk infants for personalized treatments and interventions, including dietary modifications and pharmaceutical therapies. It also provides insights into maternal and neonatal health, helping to prevent complications like gestational diabetes and



preeclampsia. Such prenatal screening, incorporated into routine newborn healthcare, facilitates early detection and management of metabolic and renal diseases, allowing for individualized treatment plans and preventive measures. This data also informs research for new strategies to improve newborn health and reduce the burden of these illnesses. By implementing preventive healthcare strategies and educating parents, healthcare providers can promote health equity and better outcomes for all newborns.

7. Conclusion

The Integration of umbilical cord blood lipid profiles with liver and renal function tests represents a promising approach to understanding fetal metabolic health and its implications for long-term health outcomes. By elucidating the complex interplay between lipid metabolism and organ function during fetal development, clinicians and researchers can advance prenatal screening strategies and interventions aimed at promoting optimal maternal and neonatal health.

References

- Ahluwalia A, Tiwari S, Dubey K, et al. Cord blood lipid profile in term newborns: its correlation with maternal lipid profile and intrauterine growth. *J Clin Neonatol.* 2014;3(2):77-80.
- Bhat BV, Kumar A, Oommen R, et al. Umbilical cord blood lipid profile and association with anthropometric measures of newborns. *Indian Pediatr.* 2015;52(10):867-869.
- Bhattacharjee J, Kumar V, Upadhyay R, et al. Evaluation of renal functions and lipid profile in neonates with intrauterine growth retardation. *Indian J Clin Biochem.* 2018;33(3):310-314.
- Singh Y, Singh N, Dixit R, et al. Correlation of umbilical cord blood lipid profile with maternal lipid profile and fetal outcome. *Indian J Med Biochem.* 2018;22(1):15-19.
- Devi SA, Nayak BS, Garg A, et al. Umbilical cord blood lipid profile and its association with birth weight in North Indian newborns. *J Clin Neonatol.* 2015;4(4):237-240.
- Goyal A, Goyal S, Garg P, et al. Correlation of umbilical cord blood lipid profile with maternal lipid profile and neonatal outcome. *Indian J Pediatr.* 2015;82(9):809-813.
- Singh H, Jain M, Budania SK, et al. Correlation of umbilical cord blood lipid profile with maternal blood lipid profile and association with intrauterine growth retardation. *Int J Reprod Contracept Obstet Gynecol.* 2018;7(8):3359-3363.
- Rai S, Khatri S, Tiwari SC. Study of umbilical cord blood lipid profile and its association with maternal lipid profile and neonatal birth weight. *J Clin Neonatol.* 2018;7(3):144-148.
- Mathew A, Raveendranath V, Jose R, et al. Cord blood lipid profile in newborns of hypertensive mothers. *Indian J Clin Biochem.* 2017;32(3):334-338.
- Sharma D, Sharma P, Soni D, et al. Evaluation of renal and liver functions in newborns with intrauterine growth restriction. *Int J Contemp Pediatr.* 2016;3(3):781-786.
- Rani A, Jain S, Dang A. Study of renal function tests in neonates with intrauterine growth restriction. *Int J Contemp Pediatr.* 2017;4(6):2212-2216.
- Verma N, Tripathi S, Gupta A, et al. Study of umbilical cord blood lipid profile and its association with fetal outcome. *Indian J Clin Biochem.* 2016;31(1):42-46.